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Impact of chronic kidney disease on carotid
plaque vulnerability
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Objective: Little is known about the effect of chronic kidney disease (CKD) on plaque morphology in cerebral vessels. We
therefore analyzed plaque composition andmetabolic and chemical parameters with regard to clinical outcome in patients
with advanced carotid artery stenosis (>70%) and normal or impaired renal function.
Methods: Carotid endarterectomy plaques were collected from 114 patients, 51 with CKD and 63 without CKD (mean
estimated glomerular filtration rate, 49 9 vs 88 14 mL/min), and analyzed by histology and immunohistochemistry.
Serum levels of matrix metalloproteinases (MMP-1, -2, -3, -7, -8, and -9), calcium, phosphate, parathyroid hormone,
fetuin-A, osteoprotegerin, and inflammatory factors, including fibrinogen, and high-sensitive C-reactive protein (hsCRP)
were measured by appropriate enzyme-linked immunosorbent assay.
Results:Compared with patients without CKD, patients with CKD had significantly more early-stage (11.2% vs 2.8%, P
.002) and end-stage (7.4% vs 0.2%, P  .036) calcification, unstable (50.8% vs 20.4%, P  .001) and ruptured (53.1% vs
32.8%, P  .035) lesions, and a significantly lower amount of collagenous fibers (39.2% vs 54.6%, P  .001). Serum
samples of CKD patients had significantly enhanced levels of fibrinogen (393  88 vs 331  60 mg/dL, P  .018),
hsCRP (1.7  2.9 vs 0.8  0.9 mg/dL; P  .042), parathyroid hormone (47.3  24.1 vs 32.8  12.2 ng/L, P  .010),
fetuin-A (0.21  0.05 vs 0.18  0.04 mg/mL, P  .039), and MMP-7 (13.0  5.3 vs 8.3  3.0 ng/mL; P < 0.001).
The incidence of cerebrovascular events >6 months before carotid surgery was significantly increased in CKD patients
(84.0% vs 26.2% P < .001).
Conclusions: In patients with CKD and advanced carotid artery stenosis, morphologic changes in plaque composition may
contribute to plaque vulnerability and consequently to the risk of cerebrovascular events. Furthermore, relevant serum
markers of inflammation, vascular calcification, and vessel wall degradation might be an indication of stroke risk in CKD
patients. ( J Vasc Surg 2011;54:1643-9.)
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CCarotid plaque vulnerability depends on various patho-
logic mechanisms such as neovascularization, inflamma-
tion, calcium deposition, and vessel wall remodeling.1-3
Cardiovascular complications and the risk of ischemic
stroke are markedly increased in patients with chronic
kidney disease (CKD), with a higher prevalence of prema-
ture arterial plaque formation and 20-fold increased cardio-
vascular mortality compared with individuals with normal
kidney function.4-7
Coronary artery calcification and the calcium score are
already accepted as independent predictors of future cardiac
events.8-12Carotid atherosclerotic lesions ofCKDpatients are
also frequently calcified, with a considerable increase in vessel
wall stiffness.5-7 Furthermore, patients with CKD have signif-
icantly reduced survival after carotid endarterectomy (CEA)
compared with patients without renal insufficiency.
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doi:10.1016/j.jvs.2011.05.049Calcification is mainly analyzed by ultrasound imaging.
his method, however, does not allow for the reliable quan-
ification of calcification and plaque vulnerability.5,7,13 Deg-
adation of the vessel wall, particularly by matrix metallopro-
einases (MMPs), together with an increased inflammatory
eaction, are the main reasons for plaque progression toward
upture and consequent neurologic symptoms.14-16 Further-
ore, several studies and our own data have already demon-
trated increased levels ofMMPs in the blood of patients with
dvanced carotid atherosclerosis.17-20 CKD is also associated
ith elevation of some MMPs.21
At present, the effect of CKD on carotid plaque mor-
hology and plaque vulnerability is unknown. The aim of
ur study was therefore to analyze the composition of
therosclerotic carotid plaques in patients with and without
KDundergoingCEA. Potential markers of carotid plaque
nstability and CKD, such as MMPs, and inflammatory,
etabolic, and chemical indicators were determined in the
tudy patients. Clinical outcomes were evaluated in both
roups and correlated with histologic and laboratory data.
ATERIALS AND METHODS
Study patients. The retrospective study included 218
onsecutive patients with carotid artery stenosis 70% as
etermined by ultrasound imaging22 who underwent ever-
ion CEA23 betweenMay 2004 and November 2008 at the
linic for Vascular Surgery of Klinikum rechts der Isar,
echnische Universität, München. The Local Ethics Com-
1643
e
i
fi
p
i
s
a
a
a
p
v
n
a
c
c
r
c
c
d
t
H
a
(
d
1
M
p
b
.
JOURNAL OF VASCULAR SURGERY
December 20111644 Pelisek et almittee approved the study and all patients gave written
informed consent.
The main study criterion for patient grouping was an
estimated glomerular filtration rate (eGFR) according to
the Kidney Disease Improving Global Outcomes24: CKD
patients at stage 1 and 2 (GFR 60 mL/min) vs CKD
patients at stage 3 and 4 (15-59 mL/min). The study
excluded patients requiring dialysis (stage 5, eGFR 15
mL/min) because the incidence of cerebrovascular death in
this population is 15- to 30-times higher than in the general
population.25
Patients were selected for study inclusion by the avail-
ability of high-quality plaque specimens and blood samples,
a complete medical history, and availability of magnetic
resonance imaging data. Only 114 individuals with ad-
vanced carotid artery stenosis met these criteria: 51 carotid
artery patients with CKD and 63 without CKD.
The indication for CEA in patients with advanced
carotid artery stenosis was based on the recommendation of
the German Society for Vascular Surgery, which concluded
that CEA significantly reduces the risk of stroke in patients
aged 75 years with a carotid diameter reduction of
70%.26 The systolic and diastolic blood pressure data
were mean values of three measurements at different inter-
vals on the hospital admission day by an experienced nurse
trained in blood pressure measurement.
Histology and immunohistochemistry of carotid
plaques. Standard eversion CEA technique23 was used to
remove the intima of the artery together with all plaque
components. The plaque was immediately transferred into
4% formalin, separated 24 hours later into segments of 3 to
4 mm, and embedded in paraffin. Sections (2-3 m) were
Fig. Various degrees of calcification are shown in carotid
stage, calcified areas are observed sporadically (*granular
shown. c, The end stage of the disease presents with ho
Elastin van Gieson staining; magnification bar  50 mroutinely stained with hematoxylin and eosin (HE) and 1lastin van Gieson (EvG) to assess plaque structure, stabil-
ty, the extent of the necrotic core and calcium deposits,
brous cap thickness, and the cellular composition of the
laques. Plaque characterization was performed by two
ndependent and experienced investigators, blinded to the
tudy group.
Digital photographs were taken of each stained sample
nd computer analyzed. The calcified, soft, and collagenous
reas were labeled, and their content displayed as a percent-
ge of the total plaque area. Calcified, collagenous, and soft
laques were defined as follows: calcified areas were dark
iolet areas in EvG staining (Fig); soft plaque was defined as
oncollagenous necrotic core, negative for EvG staining;
nd collagenous areas were defined as collagen-rich ne-
rotic core, positive for EvG staining.
From our experience and a study of 526 symptomatic
arotid patients by Redgrave and Rothwell,27 we catego-
ized atherosclerotic plaques as unstable when the fibrous
ap was thinner than 100 to 150 m over a large necrotic
ore. Quantification was performed semiquantitatively by
ifferentiation between the absence and the strongly posi-
ive occurrence of the analyzed parameters.
The following primary antibodies (all from Dako,
amburg, Germany) were used: anti-smooth muscle cell
ctin (clone HHF35, dilution 1:200), anti-Factor VIII
clone F8/86, dilution 1:500), anti-CD68 (clone KP1,
ilution 1:2,000), and anti-CD45 (clone 2B11, dilution
:100). Visualization was performed with APAAP Chem-
ate Detection Kit (Dako).
Serum sampling and sample analyses. Blood sam-
ling was performed 2 days before surgical intervention
y vein puncture. Venous bloodwas centrifuged at 2000g for
s of patients with chronic kidney disease. a, In the initial
talline or #sheet-like/amorphous). b, Advanced stage is
eneous areas, often with crystalline structures (arrow).lesion
/crys
mog0 minutes at 20°C and stored at 70°C until analysis.
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Volume 54, Number 6 Pelisek et al 1645Serum indicators, such as blood urea nitrogen, creatinine,
calcium, phosphate, and red cell, white cell, and platelet
counts were measured according to standardized tech-
niques in the Institute of Clinical Chemistry at our institu-
tion. The eGFR was calculated by using the four-variables
Modification of Diet in Renal Diseases formula.24
MMPs were quantified in serum samples using Quan-
tikine enzyme-linked immunosorbent assay (ELISA) for
human MMP-1, -2, -3, -7, -8, and -9 (R&D Systems,
Wiesbaden-Nordenstadt, Germany), according to the
manufacturer’s protocol. Fibrinogen activity was deter-
mined by measuring the clotting time (Dade Behring,
Schwalbach, Germany). ELISA kits were used to measure
high-sensitive C-reactive protein (Life Diagnostics, West
Chester, Pa), serum fetuin A (Biovendor GmbH, Heidel-
berg, Germany), and the concentration of total osteopro-
tegerin (R&D Systems). The blood vessel rigidity (pulse
pressure) was calculated as a difference between systolic and
diastolic blood pressure.
Statistical analysis. Differences between groups are
reported as a mean  standard deviation for continuous
variables or as a percentage for categoric variables. The
one-sample Kolmogorov-Smirnov test was performed to
check for normal distribution. Non-normally distributed
samples were transformed by common transformation
methods (log, LN, square root), whether normality can be
achieved. The t test was used for normally distributed
samples, the Mann-Whitney approach for nonparametric
samples, and the Fisher exact test for nominal variables.
Correlations between continuous variables were quantified
by using the Spearman rank correlation coefficient. Linear
regression analysis was performed to adjust the results for
relevant clinical parameters such as age, sex, smoking, cor-
onary heart disease, or neurologic symptoms. Correction
for multiple testing was determined by using the Benjamini
and Hochberg approach that considers the fraction of the
false positives over the amount of tests declared significant
and does not reduce the overall statistical power.19 Values
of P  .05 were considered statistically significant.
RESULTS
Patient characteristics. The basic characteristics of
the study patients, associated diseases, and medical treat-
ment are summarized in Table I. No significant differences
were observed between the study groups in age, sex, body-
mass index, diabetes, or smoking. Most CKD patients were
at stage 3, with the exception of four individuals at stage 4.
The only differences between the study groups were the
systolic and diastolic blood pressure, which were both
significantly increased in patients with CKD. Pulse pressure
was significantly reduced in CKD patients (60.5  9.4 vs
65.8 12.3, P .041). Hypertension was slightly but not
statistically significantly more prevalent in CKD patients
(P  .129). Study patients were a mean age of 72.7  6.8
years. No differences were observed in medical treatment
between patients with or without CKD: 97% of patients
were receiving aspirin and 70% were taking statins. (Histologic characteristics of carotid plaques. Tissue
amples were analyzed for hemorrhage, calcification, soft or
ollagenous plaque, lesion stability, cellularity, neovascu-
arization, and appearance of inflammatory cells (Table II).
n addition, different stages of calcification were identified
n calcium deposits: initial, advanced, and end-stage (Fig).
nitial and advanced stages possessed mainly heteroge-
eous, amorphous, and diffuse structures and were classi-
ed as early calcification (Fig, a and b). End-stage cal-
ification was mainly homogenous with a sheet-like
ppearance, clearly distinguished from the surrounding
issue (Fig, c). Furthermore, at the early stage of calcifica-
ion, neovessels were frequently observed adjacent to the
alcified area together with macrophages and inflammatory
ells. In contrast, at the end-stage of calcification, large
reas were often acellular and avascular.
Compared with patients without CKD, patients with
mpaired renal function exhibited a significantly higher
ercentage of early (11.2% vs 2.8%, P  .002) and end-
tage (7.4% vs 0.2%; P  0.036) calcification (Table II).
he occurrence of soft plaques was similar in both groups,
ut patients with CKD had a significantly lower percentage
f collagenous plaques than those without CKD (39.2% 
9.6% vs 54.6%  22.2%, P  .001), and the cellularity
ithin the plaque was also significantly reduced by 23.1% in
hese patients (P  .024). Finally, compared with carotid
atients without CKD, patients with impaired renal func-
ion had a significantly higher percentage of unstable
50.8% vs 20.4%, P .001) and ruptured lesions (53.1% vs
2.8%; P  .035). After correction for multiple testing,
alcification (P  .001) and carotid plaque instability (P 
004) were still significantly different between the groups
able I. Characteristics of study patients with and
ithout chronic kidney disease (CKD)
arametera
CKD
(n  51)
No CKD
(n  63) P
ge, years 73.3  7.4 72.1  6.2 .137
ale sex 58.2 72.5 .117
ody mass index, kg/m2 25.7  4.5 26.6  4.1 .274
lood pressure, mm Hg
Systolic 143.8  16.8 136.2  11.6 .025b
Diastolic 78.7  7.2 75.0  7.4 .029b
ypertension 92.5 79.1 .129
ulse pressure, mm Hg 60.5  9.4 65.8  12.3 .041b
iabetes mellitus 28.2 27.7 .99
yperlipidemia 69.6 76.3 .624
moking 39.5 42.5 .821
spirin 97.6 97.2 .719
CE inhibitors 48.6 41.1 .495
-Blocker 69.2 65.0 .239
iuretics 54.1 35.6 .119
alcium channel blocker 35.1 15.6 .069
tatins 70.3 65.0 .606
CE, Angiotensin converting enzyme.
Continuous data are the mean standard deviation of the analyzed groups;
ategoric data are given as a percentage.
Statistically significant differences between the groups.Table II).
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rect proportional relationship between the state of calcifi-
cation and plaque stability (r  –0.296, P  .004). The
amorphous state of calcification (early stage) highly corre-
lated with plaque instability (r  –0.398, P  .001) and
rupture (r 0.323, P .002). Adjustment of calcification
for other histologic features further confirmed the correla-
tion between the extent of calcification and risk of plaques
rupture (  0.336, P  .019). Multivariate regression
analysis to estimate the influence of various clinical param-
eters on the carotid plaque calcification in patients with
CKD showed age, sex, smoking, diabetes, and neurologic
symptoms were not significantly correlated with plaque
calcification.
Serum characteristics. According to the study criteria
for patients with impaired renal function, creatinine, blood
urea nitrogen, and eGFR differed significantly between
patients with and without CKD (Table III), as did the
inflammatory marker fibrinogen (393  88 vs 330  59
mg/dL, P .006). The values of hsCRPwere not normally
distributed. After LN-transformation, the values of hsCRP
followed a normal distribution, and the comparison of
patient groups with and without CKD by t test showed
significant differences (P  .042; Table III).
In serum of patients with CKD compared with individ-
uals with normal kidney function, the levels of intact para-
thyroid hormone (PTH; 47.3 24.1 vs 32.8 12.2 ng/L,
P  .010) and fetuin-A (0.21  0.05 vs 0.18  0.04
Table II. Carotid plaque characteristics of patients with
and without chronic kidney disease (CKD)
Parametera
CKD
(n  51)
No CKD
(n  63) Pb Pc
Thrombus, % 14.2  12.7 8.8  7.9 .169 .232
Calcification,d %
Early-stage 11.2 (0-44) 2.8 (0-29) .002 .006
End-stage 7.4 (0-66) 0.2 (0-20) .036 .057
Total calcification,e % 20.3  16.9 9.1  8.2 .001 .001
Soft plaque,e % 26.2  18.5 27.4  19.1 .776 .854
Collagenous
plaque,e % 39.2  19.6 54.6  22.2 .001 .006
Plaque instabilityf 50.8 20.4 .001 .004
Plaque rupturef 53.1 32.8 .035 .064
Cellularityg 76.9 100 .024 .053
Neovascularizationg 105.4 100 .724 .885
Inflammatory
infiltratesg 106.8 100 .945 .945
aData are presented as mean  standard deviation, mean (range), or as a
percentage.
bBivariate statistical analysis (Mann-Whitney test).
cCorrection for multiple testing (Benjamini-Hochberg approach).
dNon-normal distribution, Mann-Whitney test, mean (range) of the plaque
volume.
eNormal distribution, t test, given as mean  standard deviation of the
plaque volume.
fNominal distribution, Fisher exact test.
gSemiquantitative analysis between no occurrence and strongly positive
occurrence of the parameter; patients without chronic renal failure were set
as 100%.mg/mL, P .042) were also significantly increased (Table .II). In contrast, no differences in serum calcium, serum
hosphate, or osteoprotegerin concentrations were ob-
erved between the study groups. To prove whetherMMPs
ncreased in patients with advanced carotid artery stenosis
nd CKD, various MMPs in the serum of the study patients
ere tested. Of the six measured MMPs (MMP-1, -2, -3,
7, -8, and -9), only MMP-7 was significantly increased in
atients with CKD compared with patients with normal
enal function (13.0 5.3 vs 8.3 3.0 ng/mL, P .001).
Correlation between serum parameters and plaque
omposition. Correlation coefficients were calculated to
ain an insight into the possible relationships between
arious serum parameters and plaque composition. Nega-
ive correlations were found between early-stage calcifica-
ion and collagenous plaque content (r  –0.235, P 
049), cellularity (r  –0.325, P  .009), and eGFR (r 
0.288, P .038). Positive correlations were observed for
arly calcified areas and blood urea nitrogen (r  0.337,
 .008), creatinine (r  0.325 P  .009), MMP-3 (r 
.347, P .008), and MMP-7 (r 0.261, P .043). For
nd-stage calcification, negative correlations were observed
or soft plaque content (r  –0.364, P  .001) and eGFR
r  –0.297, P  .033), and positive correlations for
nfiltrates (r 0.261, P .047), creatinine (r 0.293 P
able III. Serum parameters of patients with and
ithout chronic kidney disease (CKD)
arameter
CKD
(n  51)
No CKD
(n  63) Pa
erum creatinine,
mg/dL 1.4  0.4 0.8  0.2 .001
lood urea nitrogen,
mg/dL 23.0  8.8 15.8  4.4 .001
GFR, mL/min/
1.73 m2 49.6  9.9 88.7  14.8 .001
erum calcium, mmol/L 2.17  0.15 2.22  0.17 .349
erum phosphate,
mmol/L 3.41  0.59 3.34  0.61 .579
ntact PTH, ng/L 47.3  24.1 31.8  12.2 .010
ibrinogen, mg/dL 393  88 330  59 .006
sCRP,b mg/dL 1.7  2.9 0.8  0.9 .042
emoglobin, g/dL 13.2  1.8 13.9  1.4 .018
ematocrit, % 39.5  4.9 40.9  5.1 .202
rythrocytes, T/L 4.3  0.5 4.6  0.5 .018
eukocytes, 109/L 7.6  1.9 7.2  1.7 .161
hrombocytes, T/L 243  68 236  72 .413
etuin-A, mg/mL 0.21  0.05 0.18  0.04 .039
steoprotegerin, ng/mL 3.19  0.18 3.12  0.11 .116
MP, ng/mL
-1 3.6  2.9 3.4  2.9 .835
-2 260  77 261  89 .923
-3 12.5  7.2 10.6  4.9 .228
-7 13.0  5.3 8.3  3.0 .001
-8 13.2  5.9 13.6  7.1 .890
-9 209  53 191  71 .323
GFR,Estimated glomerular filtration rate; hsCRP, high-sensitive C-reactive
rotein; MMP, matrix metalloproteinase; PTH, parathyroid hormone.
Normal distribution, t test.
Data for hsCRP were not normally distributed and were therefore LN-
ransformed to achieve normal distribution.044), MMP-1 (r  0.317 P  .028), and MMP-7 (r 
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Volume 54, Number 6 Pelisek et al 16470.403 P .007). Values of hsCRP in the blood of patients
with advanced carotid artery stenosis correlated signifi-
cantly with the calcium content within the plaque. PTH
correlated negatively with eGFR (r  –0.285, P  .017)
and plaque calcification (r  –0.316, P  .003).
Multivariate linear regression analysis was performed to
determine clinical parameters that might independently
contribute to the increased level of MMP-7. Neurologic
symptoms, plaque stability, smoking, coronary disease, age,
or sex were not significant determinants of the increased
MMP-7 concentration in patients with CKD. Interestingly,
however, the level of MMP-7 in serum was significantly
correlated with hypertension (  0.304, P  .024) and
pulse pressure (  –0.271, P  .029).
Analysis of cerebrovascular events. Finally, we ana-
lyzed neurologic symptoms and cerebrovascular risk in our
study cohort. For this purpose, a detailed analysis of the
occurrence of recent neurologic symptoms was performed
at intervals of 2 days, 14 days, and 6 months before
CEA. In addition, we analyzed for temporally more remote
neurologic events or silent infarcts (6 months before
CEA), detected by medical history or by brain imaging
studies (Table IV). Recent neurologic symptoms, deter-
mined as transient ischemic attack or stroke 6 months
before CEA did not differ between patients with CKD
(44.4%) and those without CKD (47.1%; P .851). How-
ever, significant differences were observed for cerebral le-
sions 6 months: 84.0% of patients with CKD had sus-
tained a stroke (6 months before CEA) or showed signs
of a silent brain infarction compared with 26.2% of individ-
uals with normal kidney function (P  .001). The sub-
group analysis regarding recent (6 months) and old (6
months) occurrence of neurologic symptoms demon-
strated significantly higher cerebrovascular events in CKD
Table IV. Neurologic characteristics of patients with and
without chronic kidney disease (CKD)
Parameter
CKD
(n  51)
No CKD
(n  63)
Pa(%) (%)
Transient ischemic attack or
stroke 44.4 47.1 .851
2 days 3.9 5.9 .828
14 days 29.4 31.4 .676
6 months 9.8 17.6 .572
6 months 84.0 26.2 .001
Insults/silent brain infarctions
(6 months)b
2 daysc 80 50 ND
14 daysc 94.4 7.7 .001
6 monthsc 87.5 28.6 .001
6 months (asymptomatic) 48.1 13.3 .001
ND, Not determined.
aNominal distribution, Fisher exact test.
bHistory of cerebrovascular events determined by magnetic resonance im-
aging or computed tomography from patient anamnesis.
cAdditional previous cerebrovascular events for the subgroups of patients of
the upper part of the Table.patients (P  .001; Table IV). An interesting finding was shat asymptomatic patients with CKD had also significantly
ore brain lesions 6 months compared with individuals
ithout CKD (48.1% vs 13.3%, P  .001).
ISCUSSION
The results of the present study indicate that CKD is
ssociated with significant changes in the composition of
arotid plaques in patients with carotid stenosis 70%. As
xpected, CKD patients had significantly more calcified
laques than individuals without CKD, and, interestingly,
he lesions of CKD patients were also more frequently
nstable or ruptured. CKD patients had significantly en-
anced serum levels of the inflammatory markers fibrino-
en and hsCRP and factors associated with vascular calcifi-
ation such as PTH and fetuin-A.
Of particular interest was the significant difference in
he prevalence of remote strokes or silent infarcts. These
eurologic events were significantly more common in CKD
atients (84%) than in individuals without CKD (26%).
obayashi et al28 showed an independent association be-
ween stages of reduced eGFR and a higher prevalence of
ilent brain infarction. Thus, our results confirm the link
etween carotid plaque instability and cerebrovascular
vents in patients with CKD.
Results of our histologic investigations confirmed the
igher degree of plaque calcification in patients with im-
aired renal function. However, compared with studies in
hich ultrasound imaging was used to detect calcified
ascular regions,5,7,9 the amount of calcification in our
arotid specimens was quite low, averaging 21% in patients
ith CKD. This discrepancy occurred because we mea-
ured calcification in the intima obtained by our surgical
echnique. In contrast, ultrasound imaging is not able to
istinguish between intima and media. However, altera-
ions in the intima of the carotid artery are of particular
linical relevance, frequently causing stroke or transient
schemic attack by plaque rupture.
We were also able to differentiate between various
egrees of calcification, from early-stage to end-stage. An
nteresting finding was that in patients with CKD, 11.2% of
alcified plaques were at an early stage of calcification
ompared with 2.8% in patients without CKD. In addition,
arotid plaques of patients with CKD had significantly
ewer collagen fibers and reduced cellularity. CKD leads to
disturbed calcium/phosphate balance, with an increase in
alcium and phosphates in the blood and consequently to
nhanced accumulation of these agents within atheroscle-
otic plaques. Calcium phosphate in turn induces the re-
ease of proinflammatory cytokines, the death of human
ascular smooth muscle cells, and as a consequence, an
verall reduction of collagen synthesis and cell number in
he affected plaque.29 Thus, our results indicate a possible
ffect of enhanced calcification of atherosclerotic lesions in
KD patients on plaque composition, which may lead to
nhanced plaque instability and rupture.
To identify markers that could reflect plaque patho-
hysiology in CKD patients, we also investigated various
erum parameters. Fibrinogen and hsCRP were signifi-
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December 20111648 Pelisek et alcantly increased in carotid patients with CKD, highlighting
the role of inflammation in the rapid progression of athero-
sclerotic lesions toward vulnerable plaques. Furthermore,
our results confirmed the data of Zoccali et al,30 who found
that plaque formation was independently predicted by
background lesion burden and serum CRP levels.
MMPs were chosen as biomarkers for carotid athero-
sclerotic plaques because of their important role in the
destabilization of atherosclerotic plaques.14-16,31We found
a significantly higher level of MMP-7 in the serum of
patients with CKD. Furthermore, correlations were found
between MMP-1, -3, and -7 in the serum of carotid pa-
tients and the extent of plaque calcification and eGFR.
MMP-7 is mainly expressed bymacrophages and inflamma-
tory cells14,32 and is especially required for proteoglycan
degradation and macrophage infiltration.16,33
Because MMP-7 is also involved in the induction of
apoptosis of vascular smooth muscle cells (VSMC),34 the
MMP-7 level in the serum might reflect the state of inflam-
mation and increased amount of apoptotic VSMCs within
atherosclerotic lesions. Inflammation and apoptosis both
contribute to plaque vulnerability and rupture. Our results
are in concordance with these findings: the level of MMP-7
in serum significantly correlated with the amount of inflam-
matory cells in the plaque and with the reduction in colla-
gen fibers. Thus, increased MMP-7 level could reflect the
increased VSMCs apoptosis and inflammation. Further-
more, MMP-7 and hypertension are also linked through a
mechanism of vasoregulation by various post-transcrip-
tional and transcriptional mechanisms.35-37
Our study has some limitations: First, we acknowledge
that HE and EvG staining of calcium deposition are not the
optimal histologic methods. However, the protocol of
plaque tissue fixation in formalin immediately after surgical
resection in our hospital did not allow us to use other
methods. This limitation notwithstanding, HE and EvG
have previously been used for quantification of plaque
calcification.38
Second, we compared patients with advanced carotid
artery stenosis (70%), with or without CKD, undergoing
vascular surgery, without including individuals with only
CKD and without any carotid artery burden. Thus, our
results might be different in patients with less or absence of
severe carotid artery stenosis.
Finally, our single-center study had a relatively small
number of participants. Thus, we cannot be sure that other
patients, medically managed differently from our patients,
would have the same determinants of plaque behavior.
CONCLUSIONS
Our results demonstrate that unstable atherosclerotic
plaques are found more frequently in carotid artery disease
patients with CKD than in those with normal renal func-
tion. Irrespective of enhanced calcification, we have found
that CKD also leads to additional changes in plaque com-
position, such as reduced cellularity, reduced collagen, and
increased inflammation, which may lead to plaque instabil-
ity and rupture. These morphologic differences in plaqueomposition are associated with an increased prevalence of
erebrovascular events in patients with CKD. Further stud-
es are necessary to better define the pathophysiology of
arotid plaque development in patients with CKD to im-
rove clinical decisionmaking in these challenging patients.
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